Table 4.
Model 1 | Model 2 | Model 3 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Coef.a | SE | P | Coef.a | SE | P | Coef.a | SE | P | |||
Age at baseline | −0.14 | 0.07 | 0.067 | −0.13 | 0.07 | 0.074 | −0.11 | 0.08 | 0.1766 | ||
Years of education | 0.03 | 0.03 | 0.141 | 0.05 | 0.04 | 0.182 | 0.06 | 0.04 | 0.097 | ||
Female (Ref: Male) | −0.61 | 0.17 | P<0.001 | −0.60 | 0.17 | P<0.001 | −0.55 | 0.17 | 0.002 | ||
Racial/ethnic minority (Ref: Non-Hispanic white) | −0.52 | 0.22 | 0.017 | −0.54 | 0.22 | 0.014 | −0.63 | 0.23 | 0.006 | ||
Mental Health | |||||||||||
Depression (Ref: No) | 0.26 | 0.21 | 0.219 | 0.30 | 0.22 | 0.163 | |||||
Schizophrenia/Schizoaffective Disorder (Ref: No) | 0.11 | 0.19 | 0.571 | 0.17 | 0.19 | 0.390 | |||||
Substance Abuse or Dependence (Ref: No) | −0.20 | 0.18 | 0.270 | −0.30 | 0.18 | 0.090 | |||||
1st Generation Antipsychotic (Ref: No) | −0.76 | 0.31 | 0.014 | −0.89 | 0.31 | 0.004 | |||||
2nd Generation Antipsychotic (Ref: No)b | −0.42 | 0.20 | 0.033 | −0.51 | 0.20 | 0.011 | |||||
Physical Health | |||||||||||
High Cholesterol (Ref: No) | −0.09 | 0.19 | 0.622 | ||||||||
Diabetes (Ref: No) | 0.15 | 0.21 | 0.473 | ||||||||
Cancer (Ref: No) | 1.05 | 0.45 | 0.019 | ||||||||
CRF (6MWT, 50m increase)c | 0.12 | 0.04 | 0.009 | ||||||||
Analytic N | 303 | 299 | 292 | ||||||||
R2 | 0.072 | 0.107 | 0.149 | ||||||||
R2 change | 0.035* | 0.042* | |||||||||
F Statistic | 5.74** | 3.83** | 3.73** |
Notes: Calculated using ordinary least squares regression.
2nd generation includes participants taking only second generation/atypical antipsychotics and those taking both a first- and second-generation antipsychotic.
Cardiorespiratory fitness (six-minute walk test).
p<0.05;
p<0.001